Drug Trial Radar · NCT06016855
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
6
Planned (sponsor's estimate)
Start
May 31, 2024
Primary completion
May 28, 2027
Study completion May 28, 2028
Sponsor
- Lead sponsor
- Vanderbilt-Ingram Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase IV trial evaluates how well giving standard of care (SOC) peptide receptor radionuclide therapy (PRRT) after SOC surgical removal of as much tumor as possible (debulking surgery) works in treating patients with grade 1 or 2, somatostatin receptor (SSTR) positive, gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have spread from where they first started (primary site) to the liver (hepatic metastasis). Lutetium Lu 177 dotatate is a radioactive drug that uses targeted radiation to kill tumor cells. Lutetium Lu 177 dotatate includes a radioactive form (an isotope) of the element called lutetium. This radioactive isotope (Lu-177) is attached to a molecule called dotatate. On the surface of GEP-NET tumor cells, a receptor called a somatostatin receptor binds to dotatate. When this binding occurs, the lutetium Lu 177 dotatate drug then enters somatostatin receptor-positive tumor cells, and radiation emitted by Lu-177 helps kill the cells. Giving lutetium Lu 177 dotatate after surgical debulking may better treat patients with grade 1/2 GEP-NETs
Conditions
- Digestive System Neuroendocrine Tumor G1
- Digestive System Neuroendocrine Tumor G2
- Metastatic Digestive System Neuroendocrine Neoplasm
- Metastatic Malignant Neoplasm in the Liver
- Pancreatic Neuroendocrine Tumor G1
- Pancreatic Neuroendocrine Tumor G2
Interventions
Tumor DebulkingProcedure
Undergo surgical debulking
Lutetium Lu 177 DotatateDrug
Given by IV
Computed TomographyProcedure
Undergo Computed Tomography
Magnetic Resonance ImagingProcedure
Undergo Magnetic Resonance Imaging
Copper Cu 64 DotatateDrug
Given by IV
Positron Emission TomographyProcedure
Undergo Positron Emission Tomography
Primary outcomes
What the sponsor says the trial is designed to measure.
- Somatostatin receptor standardized uptake values (SSTR SUV)Time frame: Up to 2 years
- Progression-free survivalTime frame: From the start of PRRT to the date the patient progresses radiographically or succumbs to the disease, assessed up to 2 years
- Overall response rateTime frame: Up to 2 years
- Overall survivalTime frame: From the start of PRRT to the date the patient progresses radiographically or succumbs to the disease, assessed up to 2 years
- Incidence of adverse eventsTime frame: Up to 2 years
- Gene mutationsTime frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.